Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
March 13, 2024 16:53 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to...
Passing of Genmab A/S’ Annual General Meeting
March 13, 2024 11:13 ET
|
Genmab A/S
Company Announcement At Genmab A/S’ Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approvedDischarge was given to the Board of Directors and the Executive Management...
Transactions in connection with share buy-back program
March 11, 2024 05:42 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
March 04, 2024 13:10 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 4, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions in connection with share buy-back program
March 04, 2024 04:29 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 4, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
March 01, 2024 18:04 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 02, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
February 29, 2024 10:48 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 29, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
February 27, 2024 15:42 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 27, 2024 15:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The...
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 26, 2024 19:45 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating...